11 Cheap Biotech Stocks to Buy According to Hedge Funds

Page 9 of 9

1. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 73 

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) tops our list for being one of the cheap biotech stocks to buy. It is a biotechnology company developing treatments for serious diseases, including eye conditions, inflammatory disorders, cancer, and rare diseases. Its strong R&D and antibody platform support long-term growth from drugs like Dupixent and new launches in oncology and respiratory care.

In Q2 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported strong results driven by Dupixent, which generated $4.34 billion in sales, exceeding expectations. However, Eylea sales declined 25%, and the FDA again declined approval for the blood cancer therapy odronextamab due to manufacturing issues at a third-party facility. The business remains confident that these issues can be resolved, as the drug is already approved in Europe and targets follicular lymphoma.

The company continues to emphasize innovation, awarding its 13th annual Regeneron Prize for Creative Innovation to early-career biomedical researchers and supporting global STEM education initiatives.

Looking ahead, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s priorities include resolving regulatory challenges for odronextamab, expanding Dupixent’s market, and advancing new oncology and respiratory launches to sustain growth despite near-term setbacks.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9